8-K: Black Hawk Acquisition Corp. to Merge with Vesicor Therapeutics, Creating Publicly Traded Biotech Firm

Black Hawk Acquisition Corp. and Vesicor Therapeutics have entered into a business combination agreement, paving the way for Vesicor to become a publicly traded company focused on p53-based cancer therapeutics.

Summary

• Black Hawk Acquisition Corp. (BKHA) has signed a Business Combination Agreement (BCA) with Vesicor Therapeutics, Inc., a biopharmaceutical company focused on p53-based cancer therapeutics delivered via microvesicles.
• The transaction values Vesicor at a pre-money equity value of $70 million.
• Upon closing, BH Merger Sub, Inc., a subsidiary of Black Hawk, will merge with Vesicor, with Vesicor becoming a wholly-owned subsidiary of Black Hawk, which will then change its name to Vesicor Therapeutics and remain Nasdaq-listed.
• Vesicor's shareholders will receive shares of Black Hawk's common stock based on a consideration ratio defined in the BCA.
• The transaction is subject to regulatory and shareholder approvals, effectiveness of a Form S-4 registration statement, and Nasdaq listing approval, with an expected completion in the fourth quarter of 2025.
• Vesicor's lead product candidate, ecm-RV/p53, has been administered to patients in Japan under the Advanced Medical Care B mechanism and the company plans to begin preclinical testing in the U.S. with the goal of submitting an IND application to the FDA in 2026.
• The combined company will focus on completing preclinical testing in the United States, submitting an IND to the FDA, and beginning Phase 1 clinical trials.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The announcement highlights a business combination that will allow Vesicor to access public markets and advance its cancer therapeutics. However, the early stage of Vesicor's development and the risks associated with the biotechnology industry temper the overall sentiment.

Positives

• Vesicor will gain access to public markets and capital to advance its ecm-RV/p53 drug candidate.
• The combined company will focus on a promising area of cancer therapeutics.
• Vesicor's management team will continue to lead the company after the merger.
• The transaction has been unanimously approved by both companies' boards of directors.

Negatives

• Vesicor's ecm-RV/p53 drug candidate is still in early development and has not been approved for use in the United States.
• The transaction is subject to various closing conditions, including regulatory and shareholder approvals, which may not be met.
• The combined company will need to raise additional capital to fund its operations and clinical trials.
• The combined company will be subject to the risks and uncertainties of the biotechnology industry.

Risks

• The Business Combination Agreement may be terminated.
• Legal proceedings may be instituted against the Company or Vesicor.
• The Business Combination may not be completed due to failure to obtain approval of the shareholders of the Company or other conditions to closing.
• Necessary regulatory approvals may not be obtained or may be delayed.
• The listing of the post-acquisition company's ordinary shares on Nasdaq may not be obtained or maintained.
• The Business Combination may disrupt current plans and operations.
• The anticipated benefits of the Business Combination may not be realized.
• Vesicor or the combined company may be adversely affected by economic, business, and/or competitive factors.

Future Outlook

The combined company will focus on completing preclinical testing in the United States, submitting an IND to the FDA, and beginning Phase 1 clinical trials.

Management Comments

• Mr. Kent Kaufman, Chief Executive Officer of Black Hawk, stated: 'Our aim is to identify a company with solid potential to disrupt an entire industry, a talented and credentialed executive team with a proven track record, and good prospects for future growth. We believe that we have found these qualities in Vesicor. We look forward to completing this transaction and working with Vesicor's management team to help them thrive as a public company while they continue to grow.'
• Luo Feng, Ph.D., Founder and Chief Executive Officer of Vesicor Therapeutics, stated: 'Our mission is to transform the lives of cancer patients and their families. We are focused on completing preclinical testing in the United States, submitting our IND to the FDA and beginning Phase 1 clinical trials.'
• Oded Levy, Board Director of Vesicor Therapeutics, stated: 'We are excited to partner with Kent and the rest of the Black Hawk team to bring Vesicor to the public markets. We believe that this transaction, if completed, will help facilitate access to the capital markets and will accelerate the validation and deployment of our ecm-RV/p53 drug candidate.'

Industry Context

This announcement reflects the ongoing trend of SPACs merging with private companies, particularly in the biotechnology sector, to accelerate their entry into the public markets.

Comparison to Industry Standards

• It is difficult to compare Vesicor to industry standards due to its early development stage.
• Comparable companies would include other early-stage biotechnology firms focused on novel cancer therapeutics.
• Success will depend on clinical trial outcomes and regulatory approvals, benchmarked against similar companies in the field.

Stakeholder Impact

• Shareholders of Black Hawk will have the opportunity to vote on the transaction.
• Vesicor's shareholders will receive shares in the combined company.
• The transaction could lead to new treatments for cancer patients.
• Employees of both companies will be integrated into the combined company.

Next Steps

• Obtain regulatory approvals.
• Obtain shareholder approvals from Black Hawk and Vesicor.
• Complete the Form S-4 registration statement.
• Close the Business Combination in the fourth quarter of 2025.
• Complete preclinical testing in the United States.
• Submit an IND to the FDA.
• Begin Phase 1 clinical trials.

Key Dates

Keywords

Vesicor Therapeutics, Black Hawk Acquisition Corporation, Business Combination, Merger, Biopharmaceutical, p53-based cancer therapeutics, microvesicles, Nasdaq, ecm-RV/p53, SPAC